December 8, 2014
Table of Contents
Tuberculosis (TB) is an infection of the lungs and respiratory system. One third of the world's people are infected with TB, and along with HIV, TB is one of the world's leading causes of death due to disease. The World Health Organization estimates that over three million women became sick with TB in 2013. Of the nine million new cases of tuberculosis in 2013, over one million occurred in people living with HIV (HIV+). The largest numbers of TB infection occur in south-east Asia (56 percent of global total), while one quarter of the nine million occurred in Africa.
In the US, the number of new TB cases reported each year has been going down since 1993. According to the Centers for Disease Control and Prevention (CDC), the number of TB cases reported in 2013 was the lowest that is has been since reporting began in 1953.
TB is caused by a bacterium called Mycobacterium tuberculosis. It spreads from person to person when an infected person coughs, sneezes, laughs, or spits. Tiny droplets of fluid from the lungs are carried in the air and can be breathed in by someone nearby. Although it can affect many parts of the body, TB usually occurs in the lungs.
Not everyone who is infected with TB bacteria develops "active" disease.
People with weakened immune systems are more likely to develop active TB disease. This includes people living with HIV, children, elderly people, and people who take drugs that suppress the immune system. Research shows that, among those with latent TB, people living with HIV are three to 12 times more likely to develop active TB disease than HIV-negative people. Treating latent TB can greatly reduce your chances of developing active TB. Treatment of latent TB protects your health as well as keeps you from spreading TB to others. You can develop active TB with any CD4 count. Studies also show that TB can worsen HIV disease progression. Having active TB disease while HIV+ is an AIDS-defining condition.
Worldwide, TB is the leading cause of death in people living with HIV in Africa, and a leading cause of death elsewhere. The WHO estimates that one third of the 35 million people living with HIV worldwide are infected with TB. The CDC recommends that HIV+ people be screened for TB when they are first diagnosed with HIV; in addition, yearly screening is recommended for HIV+ people who have repeated exposure to others with active TB (see "Diagnosing TB," below).
TB is spread through the air when an infected person coughs, sneezes or spits. It usually takes a long time for TB transmission to occur. Family members of people with TB, people living in the same house, health-care workers, and people who live in residential facilities like homeless shelters and prisons are most likely to get TB. People with latent (not active) TB do not spread the disease. Once a person with active TB starts treatment (see "TB Treatment" below), they usually cannot spread the disease after two to three weeks on treatment.
People with active TB should be separated from others until they can no longer spread the disease. If you have TB or spend time around people with TB, it is important to wear a disposable face mask. Certain types of air filters can trap the TB bacteria, and ultraviolet light can kill it.
After TB bacteria are inhaled, they settle in the lungs. People with healthy immune systems can usually fight the bacteria and keep it from multiplying. The immune system may build structures that wall off the bacteria. These structures can burst, leaving scars in the lungs. If a person's immune system is too weak and the structures burst, the bacteria can get out and enter the bloodstream. Once in the bloodstream they travel to other parts of the body including the brain, kidneys, bones, and reproductive organs, where they can cause infertility. This is called "extrapulmonary TB." Extrapulmonary TB is more likely in people with advanced HIV disease.
People with active TB disease may develop symptoms including:
It is recommended that HIV+ people get screened for TB once a year using a skin, blood, or sputum test. The skin test is called a TST (tuberculin skin test) or PPD (purified protein derivative). A small amount of "tuberculin" (a TB protein) is injected under the skin of the arm, and the test is checked or "read" two to three days later by a health care worker who looks at the spot on the arm and measures any swelling. The test is positive if the area develops a hard swelling under the skin that is bigger than 5mm. Because HIV+ people sometimes do not develop a positive TB skin test reaction even if they are infected, the TB blood or sputum tests (see below) are now the preferred tests for those living with HIV.
A TB test that is strongly recommended by the WHO for people living HIV is the Xpert MTB/RIF test. This test uses sputum (mucus or phlegm you cough up from your lungs) and takes less than three hours to give results. It tests for the genetic material of TB (TB’s DNA) and for resistance to rifampin (a drug used to treat TB; see more below) at the same time.
There is also a TB blood test, called an IGRA (interferon-gamma release assay), which measures your immune response to TB. With the IGRA test, there is no need to return to a health clinic; results are usually available within 24 hours and can be communicated by phone.
A positive TB skin, blood, or sputum test shows that you have been exposed to TB, but it does not mean you have active TB disease. Your health care provider will look at your symptoms as well as other tests, such as chest X-rays and sputum tests, before diagnosing you with active TB disease.
There are two types of treatment for TB:
If you have latent or inactive TB (infected but no symptoms), your health care provider will likely suggest that you start treatment to help your body get rid of the TB. This treatment is intended to prevent active TB from developing. Treatment typically involves nine months of an antibiotic called isoniazid (INH) plus vitamin B6 supplements. Those people living with HIV who are not taking HIV drugs may be treated with INH and B6 plus rifapentine or rifampin for only three months. The INH, B6, and rifapentine or rifampin treatment combination is not recommended for people on HIV regimens because rifapentine and rifampin can interact negatively with some HIV drugs. Your health care provider will help you decide which treatment option is best for you.
During INH and B6 treatment, your provider will draw lab tests to check for any side effects from the INH medication, such as liver inflammation. The first set of lab tests will be done after you have taken the medication for one month. Also, your provider will question you regularly about any side effects you may be having from the INH. Possible side effects from INH include:
The pyroxidine or B6 medication is taken to prevent the peripheral neuropathy symptoms that INH can cause. It is important not to drink alcohol while you are taking INH, or your liver may become badly damaged.
Treatment of active TB requires combination therapy. The usual regimen is:
These four drugs are taken daily for two months. Tests can be done to see how well the drugs are fighting the TB. If the drugs are fighting the TB well, then the treatment changes to just two drugs: isoniazid plus rifampin for four more months. Sometimes the treatment will last longer, depending on whether or not the TB is resistant to these drugs, or if the TB disease has spread through the bloodstream to other parts of the body.
Some TB drugs can interact with HIV drugs. Rifampin, for example, can interfere with protease inhibitors and non-nucleoside reverse transcriptase inhibitors. This can make it difficult to treat both diseases at the same time. If you are taking a protease inhibitor, your health care provider may make changes to your TB drugs. Your provider may also adjust your drug doses when you are being treated for both TB and HIV. Some HIV+ people may need longer TB treatment than people without HIV.
As with HIV, taking your TB drugs exactly as prescribed (good adherence) is very important. The full course of treatment must be completed, even if you feel better before you have finished taking all your drugs (symptoms usually improve after three to four weeks). This helps prevent TB from coming back and becoming resistant to drugs.
Like HIV, TB can change to become resistant to drugs, especially if a drug is used alone. This can cause the drugs to stop working. Therefore, it is important for your provider to test your TB for drug resistance. Drug-resistant tuberculosis (DR TB) must be treated with a combination of drugs. Some TB strains are now resistant to several different drugs. These strains are called multiple-drug resistant tuberculosis (MDR TB) and extensively-drug resistant tuberculosis (XDR TB). XDR TB is resistant to almost all medications used to treat TB. As a result, many more people with XDR TB die or have treatment failure.
According to the CDC, untreated TB is a greater threat to pregnant women and their babies than TB treatment. Therefore, it is important to screen for and treat TB in pregnant women. The TB skin test, the TB blood test, and the TB sputum test are safe during pregnancy. As with anyone who is not pregnant, additional tests are needed to determine if someone who tests positive for TB has active TB disease.
For pregnant women with latent or inactive TB, INH taken daily or twice weekly at a higher dose for nine months is the usual treatment. In pregnant women with active TB disease, the usual treatment is INH, rifampin, and ethambutol daily for two months followed by INH plus rifampin for seven months (for a total of nine months of treatment). It is important for pregnant women taking INH to take pyridoxine (vitamin B6) daily to help prevent nerve damage.
Pregnant women should not take streptomycin because it can cause deafness in babies. Pyrazinamide is most often not recommended during pregnancy, as its effects on the developing baby are not yet known. Other TB drugs that should be avoided during pregnancy include: kanamycin, amikacin, capreomycin, and fluoroquinolones (an entire group or type of antibiotics).
TB is a serious disease that is a leading cause of death in HIV+ people worldwide. Many people can keep TB under control and have latent, or inactive, disease. But people with weakened immune systems, including people living with HIV, are much more likely to develop active TB disease that needs treatment. In many ways, TB and HIV treatment are similar. Both diseases must be treated with a combination of drugs, since using only one drug can lead to resistance. With both TB and HIV, good adherence is a very important factor in successful treatment. But unlike HIV, TB can usually be completely cured after less than a year of treatment.